var title_f7_33_7696="Acromion types";
var content_f7_33_7696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Types of acromion morphology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The relationship between the anterior third of the acromion and subacromial structures accounts in part for the development of SIS. Three acromion types have been described: flat, curved, and hooked. The hooked acromion has the highest association with SIS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7696=[""].join("\n");
var outline_f7_33_7696=null;
var title_f7_33_7697="Sinclair scale for female pattern hair loss";
var content_f7_33_7697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Sinclair scale for female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Sperling LC, Sinclair RD, Shabrawi-Caelen LE. Alopecias. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV, et al (Eds), Saunders 2012. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7697=[""].join("\n");
var outline_f7_33_7697=null;
var title_f7_33_7698="Retinal vasculitis fluoroscein";
var content_f7_33_7698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fluorescein angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluorescein angiography showing early vessel perfusion (left) and late perivascular staining (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7698=[""].join("\n");
var outline_f7_33_7698=null;
var title_f7_33_7699="Fungal nail infection PI";
var content_f7_33_7699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Fungal nail infections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These are examples of fungal nail infections.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7699=[""].join("\n");
var outline_f7_33_7699=null;
var title_f7_33_7700="Nail fibroma";
var content_f7_33_7700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail fibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7700=[""].join("\n");
var outline_f7_33_7700=null;
var title_f7_33_7701="Drug packets abdominal CT";
var content_f7_33_7701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Drug packets on abdominal CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This CT image of a body packer with bowel obstruction illustrates the air trapping seen between the packaging materials and at the end of bags.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7701=[""].join("\n");
var outline_f7_33_7701=null;
var title_f7_33_7702="Hydrocortisone (topical): Pediatric drug information";
var content_f7_33_7702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocortisone (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=see_link\">",
"    see \"Hydrocortisone (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19861?source=see_link\">",
"    see \"Hydrocortisone (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8116177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ala-Cort;",
"     </li>",
"     <li>",
"      Ala-Scalp;",
"     </li>",
"     <li>",
"      Anu-med HC;",
"     </li>",
"     <li>",
"      Anucort-HC&trade;;",
"     </li>",
"     <li>",
"      Anusol-HC&reg;;",
"     </li>",
"     <li>",
"      Aquanil HC&reg; [OTC];",
"     </li>",
"     <li>",
"      Beta-HC&reg; [OTC];",
"     </li>",
"     <li>",
"      Caldecort&reg; [OTC];",
"     </li>",
"     <li>",
"      Colocort&reg;;",
"     </li>",
"     <li>",
"      Cortaid&reg; Advanced [OTC];",
"     </li>",
"     <li>",
"      Cortaid&reg; Intensive Therapy [OTC];",
"     </li>",
"     <li>",
"      Cortaid&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Cortenema&reg;;",
"     </li>",
"     <li>",
"      CortiCool&reg; [OTC];",
"     </li>",
"     <li>",
"      Cortifoam&reg;;",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Hydratensive Healing [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Hydratensive Soothing [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Intensive Healing Eczema [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Cooling Relief [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Easy Relief [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Intensive Healing Formula [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Plus Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Dermarest&reg; Eczema Medicated [OTC];",
"     </li>",
"     <li>",
"      Hemril&reg; -30;",
"     </li>",
"     <li>",
"      Hydrocortisone Plus [OTC];",
"     </li>",
"     <li>",
"      HydroSKIN&reg; [OTC];",
"     </li>",
"     <li>",
"      Locoid Lipocream&reg;;",
"     </li>",
"     <li>",
"      Locoid&reg;;",
"     </li>",
"     <li>",
"      Pandel&reg;;",
"     </li>",
"     <li>",
"      Pediaderm&trade; HC;",
"     </li>",
"     <li>",
"      Preparation H&reg; Hydrocortisone [OTC];",
"     </li>",
"     <li>",
"      Procto-Pak&trade;;",
"     </li>",
"     <li>",
"      Proctocort&reg;;",
"     </li>",
"     <li>",
"      ProctoCream&reg;-HC;",
"     </li>",
"     <li>",
"      Proctosol-HC&reg;;",
"     </li>",
"     <li>",
"      Proctozone-HC 2.5%&trade;;",
"     </li>",
"     <li>",
"      Recort [OTC];",
"     </li>",
"     <li>",
"      Scalpana [OTC];",
"     </li>",
"     <li>",
"      Texacort&trade;;",
"     </li>",
"     <li>",
"      U-Cort&reg;;",
"     </li>",
"     <li>",
"      Westcort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8116178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aquacort&reg;;",
"     </li>",
"     <li>",
"      Cortamed&reg;;",
"     </li>",
"     <li>",
"      Cortenema&reg;;",
"     </li>",
"     <li>",
"      Cortifoam&trade;;",
"     </li>",
"     <li>",
"      Emo-Cort&reg;;",
"     </li>",
"     <li>",
"      Hycort&trade;;",
"     </li>",
"     <li>",
"      Hyderm;",
"     </li>",
"     <li>",
"      HydroVal&reg;;",
"     </li>",
"     <li>",
"      Locoid&reg;;",
"     </li>",
"     <li>",
"      Prevex&reg; HC;",
"     </li>",
"     <li>",
"      Sarna&reg; HC;",
"     </li>",
"     <li>",
"      Westcort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10495573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent, Rectal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Rectal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10495727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=see_link\">",
"      see \"Hydrocortisone (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Children and Adults: Usual: Apply 2-3 times/day (depending on severity); may be applied up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal: Adolescents and Adults: Insert 1 application 1-2 times/day for 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulcerative colitis: One enema nightly for 21 days, or until remission occurs; clinical symptoms should subside within 3-5 days; discontinue use if no improvement within 2-3 weeks; some patients may require 2-3 months of therapy; if therapy lasts &gt;21 days, discontinue slowly by decreasing use to every other night for 2-3 weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8116386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, rectal, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortifoam&reg;: 10% (15 g) [90 mg/applicator]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetate: 1% (28.4 g, 454 g); 2% (43 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U-Cort&reg;: 1% (28 g) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetate [strength expressed as base]: 1% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as base: 0.5% (28.4 g, 30 g); 1% (1 g, 1.5 g, 15 g, 28.4 g, 30 g, 114 g, 454 g); 2.5% (20 g, 28 g, 28.35 g, 30 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ala-Cort: 1% (28.4 g, 85.2 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anusol-HC&reg;: 2.5% (30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caldecort&reg;: 1% (28.4 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Advanced: 1% (42 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Intensive Therapy: 1% (37 g, 56 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Maximum Strength: 1% (14 g, 28 g, 37 g, 56 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength: 1% (15 g, 28 g, 56 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength Intensive Healing Formula: 1% (28 g, 56 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Plus Maximum Strength: 1% (28 g, 56 g) [contains aloe, vitamin A, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocortisone Plus: 1% (28.4 g) [contains aloe, vitamin A, vitamin D, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HydroSKIN&reg;: 1% (28 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preparation H&reg; Hydrocortisone: 1% (26 g) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procto-Pak&trade;: 1% (28.4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proctocort&reg;: 1% (28.35 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProctoCream&reg;-HC: 2.5% (30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proctosol-HC&reg;: 2.5% (28.35 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proctozone-HC 2.5%&trade;: 2.5% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recort: 1% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as butyrate: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid Lipocream&reg;: 0.1% (15 g [DSC], 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid&reg;: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as probutate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pandel&reg;: 0.1% (15 g, 45 g, 80 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as valerate: 0.2% (15 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CortiCool&reg;: 1% (0.9 g, 42.5 g) [contains ethanol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength Cooling Relief: 1% (28 g) [contains aloe, ethanol 15%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength Easy Relief: 1% (36 mL) [contains aloe, ethanol 45%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scalpana: 1% (85.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as base: 1% (114 g, 118 mL); 2.5% (59 mL, 60 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ala-Scalp: 2% (29.6 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aquanil HC&reg;: 1% (120 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beta-HC&reg;: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Intensive Therapy: 1% (98 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Hydratensive Healing: 1% (113 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Hydratensive Soothing: 1% (113 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Intensive Healing Eczema: 1% (99 g) [contains aloe, vitamin A, vitamin C, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermarest&reg; Eczema Medicated: 1% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HydroSKIN&reg;: 1% (118 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as base [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediaderm&trade; HC: 2% (29.6 mL) [contains benzalkonium chloride, isopropyl alcohol; packaged with protective emollient]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as butyrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid&reg;: 0.1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as acetate [strength expressed as base]: 1% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as base: 0.5% (30 g); 1% (25 g, 30 g, 110 g, 430 g, 454 g); 2.5% (20 g, 30 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Maximum Strength: 1% (28 g, 37 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength: 1% (28 g, 56 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as butyrate: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid&reg;: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as valerate: 0.2% (15 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Westcort&reg;: 0.2% (15 g [DSC], 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as acetate [micronized]: USP: 100% (10 g, 25 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Texacort&trade;: 2.5% (30 mL) [contains ethanol 48.8%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as base [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Intensive Therapy: 1% (59 mL) [contains ethanol 45%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as butyrate: 0.1% (20 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid&reg;: 0.1% (20 mL, 60 mL) [contains isopropyl alcohol 50%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as acetate: 25 mg (12s); 30 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anu-med HC: 25 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anucort-HC&trade;: 25 mg (12s, 24s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anusol-HC&reg;: 25 mg (12s, 24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemril&reg; -30: 30 mg (12s, 24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proctocort&reg;: 30 mg (12s, 24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, rectal, as base: 100 mg/60 mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colocort&reg;: 100 mg/60 mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortenema&reg;: 100 mg/60 mL (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8116182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes foam (acetate), cream (probutate),  gel (base),  liquid (base), lotion (base), lotion (butyrate), solution (base)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10495728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal: Patient should lie on left side during administration and for 30 minutes after; retain enema for at least 1 hour, preferably all night",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Apply a thin film to clean, dry skin and rub in gently; avoid contact with eyes. Do not apply to face, underarms, or groin unless directed by physician. Do not wrap or bandage affected area unless directed by physician. Do not apply to diaper areas because diapers or plastic pants may be occlusive.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10495574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of inflammation and pruritus associated with corticosteroid-responsive dermatoses; adjunctive treatment of ulcerative colitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8116165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hydrocortisone may be confused with hydrocodone, hydroxychloroquine, hydrochlorothiazide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anusol&reg; may be confused with Anusol-HC&reg;, Aplisol&reg;, Aquasol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cortizone&reg; may be confused with cortisone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HCT (occasional abbreviation for hydrocortisone) is an error-prone abbreviation (mistaken as hydrochlorothiazide)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hytone&reg; may be confused with Vytone&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Proctocort&reg; may be confused with ProctoCream&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nutracort [multiple international markets] may be confused with Nitrocor brand name of nitroglycerin [Italy, Russia, and Venezuela]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8116264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Local adverse events presented. Adverse events similar to those observed with systemic absorption are also observed, especially following rectal use. Refer to the Hydrocortisone (Systemic) monograph for details.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream, ointment:",
"     </b>",
"     Acneiform eruptions, burning, dryness, folliculitis, hypertrichosis, hypopigmentation, irritation, itching, maceration of skin, miliaria, perioral dermatitis, secondary infection, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema:",
"     </b>",
"     Burning, pain, rectal bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppositories:",
"     </b>",
"     Allergic contact dermatitis, burning, dryness, folliculitis, hypopigmentation, itching, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10495620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrocortisone or any component",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rectal suspension: Systemic fungal infections; ileocolostomy during the immediate or early postoperative period",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10495619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use hydrocortisone retention enema with caution in patients with possible impending perforation, abscess, or other pyogenic infection; fresh intestinal anastomoses; obstruction, extensive fistulas, and sinus tracts; active or latent peptic ulcer; diverticulitis; renal insufficiency; hypertension; osteoporosis; or myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10495604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be done carefully; immunosuppression may occur; may cause inhibition of bone growth in pediatric patients",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adverse systemic effects may occur when topical steroids are used in large areas of the body, denuded areas, for prolonged periods of time, with an occlusive dressing, and/or in infants and small children; infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to larger skin surface area to body mass ratio; use with caution in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8116282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8116283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8116254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8116255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Reed, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10495729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth in pediatric patients; assess HPA axis suppression in patients using topical steroids applied to a large surface area or to areas under occlusion (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10495686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10495704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Rectal absorption is more substantial than most topical preparations; therefore, systemic effects are more common.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, biologic: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Renally, mainly as 17-hydroxysteroids and 17-ketosteroids",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10495732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19861?source=see_link\">",
"      see \"Hydrocortisone (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not decrease dose or discontinue without physician's approval; notify physician if condition being treated persists or worsens. Topical: Avoid contact with eyes; do not use for longer than directed; contact physician if no improvement is seen in 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10495744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To facilitate retention of enema, prior antidiarrheal medication or sedation may be required (especially when beginning therapy)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16000 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7702=[""].join("\n");
var outline_f7_33_7702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116177\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116178\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495573\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495727\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116386\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116182\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495728\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495574\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116165\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116264\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495620\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495619\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495604\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116282\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116283\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116254\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116255\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495729\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495686\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495704\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495732\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495744\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16000\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16000|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/48/8969?source=related_link\">",
"      Hydrocortisone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/36/35398?source=related_link\">",
"      Hydrocortisone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/46/22249?source=related_link\">",
"      Hydrocortisone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=related_link\">",
"      Hydrocortisone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19861?source=related_link\">",
"      Hydrocortisone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_33_7703="Upper abdominal anatomy";
var content_f7_33_7703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Upper abdominal anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 470px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Illustration of upper abdominal anatomy showing the relationship of the stomach (rotated to show its posterior aspect) to the pancreas and spleen, and their blood supply.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7703=[""].join("\n");
var outline_f7_33_7703=null;
var title_f7_33_7704="Funisitis";
var content_f7_33_7704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    High power photomicrograph of an umbilical vein with migration of fetal inflammatory cells into the inner third of vein wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7704=[""].join("\n");
var outline_f7_33_7704=null;
var title_f7_33_7705="Diphenhydramine (systemic): Drug information";
var content_f7_33_7705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenhydramine (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=see_link\">",
"    see \"Diphenhydramine (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/48/19207?source=see_link\">",
"    see \"Diphenhydramine (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8082074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aler-Cap [OTC];",
"     </li>",
"     <li>",
"      Aler-Dryl [OTC];",
"     </li>",
"     <li>",
"      Aler-Tab [OTC];",
"     </li>",
"     <li>",
"      AllerMax&reg; [OTC];",
"     </li>",
"     <li>",
"      Altaryl [OTC];",
"     </li>",
"     <li>",
"      Anti-Hist [OTC];",
"     </li>",
"     <li>",
"      Banophen&trade; [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Allergy Quick Dissolve [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Allergy [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Children's Allergy FastMelt&reg; [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Children's Allergy Perfect Measure&trade; [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Children's Dye Free Allergy [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Dye-Free Allergy [OTC];",
"     </li>",
"     <li>",
"      Compoz&reg; [OTC];",
"     </li>",
"     <li>",
"      Diphen [OTC];",
"     </li>",
"     <li>",
"      Diphenhist&reg; [OTC];",
"     </li>",
"     <li>",
"      Geri-Dryl;",
"     </li>",
"     <li>",
"      Histaprin [OTC];",
"     </li>",
"     <li>",
"      Nytol&reg; Quick Caps [OTC];",
"     </li>",
"     <li>",
"      Nytol&reg; Quick Gels [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's NightTime Cough [OTC];",
"     </li>",
"     <li>",
"      Q-dryl [OTC];",
"     </li>",
"     <li>",
"      Quenalin [OTC];",
"     </li>",
"     <li>",
"      Siladryl Allergy [OTC];",
"     </li>",
"     <li>",
"      Silphen [OTC];",
"     </li>",
"     <li>",
"      Simply Sleep&reg; [OTC];",
"     </li>",
"     <li>",
"      Sleep-ettes D [OTC];",
"     </li>",
"     <li>",
"      Sleep-Tabs [OTC];",
"     </li>",
"     <li>",
"      Sleepinal&reg; [OTC];",
"     </li>",
"     <li>",
"      Sominex&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Sominex&reg; [OTC];",
"     </li>",
"     <li>",
"      Theraflu&reg; Thin Strips&reg; Multi Symptom [OTC];",
"     </li>",
"     <li>",
"      Twilite&reg; [OTC];",
"     </li>",
"     <li>",
"      Unisom&reg; SleepGels&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Unisom&reg; SleepMelts&trade; [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; ZzzQuil&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Allerdryl&reg;;",
"     </li>",
"     <li>",
"      Allernix;",
"     </li>",
"     <li>",
"      Benadryl&reg;;",
"     </li>",
"     <li>",
"      Nytol&reg;;",
"     </li>",
"     <li>",
"      Nytol&reg; Extra Strength;",
"     </li>",
"     <li>",
"      PMS-Diphenhydramine;",
"     </li>",
"     <li>",
"      Simply Sleep&reg;;",
"     </li>",
"     <li>",
"      Sominex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8082507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8082170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosages are expressed as the hydrochloride salt.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic reactions or motion sickness:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 25-50 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 10-50 mg per dose; single doses up to 100 mg may be used if needed; not to exceed 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antitussive:",
"     </b>",
"     Oral: 25 mg every 4 hours; maximum: 150 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Night-time sleep aid:",
"     </b>",
"     Oral: 50 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dystonic reaction:",
"     </b>",
"     I.M., I.V.: 50 mg in a single dose; may repeat in 20-30 minutes if necessary",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8082169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/48/19207?source=see_link\">",
"      see \"Diphenhydramine (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosages are expressed as the hydrochloride salt.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic reactions or motion sickness:",
"     </b>",
"     Oral, I.M., I.V.: 5 mg/kg/day or 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-8 hours, not to exceed 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternate dosing by age:",
"     </i>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2 to &lt;6 years: 6.25 mg every 4-6 hours; maximum: 37.5 mg/day",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     6 to &lt;12 years: 12.5-25 mg every 4-6 hours; maximum: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;12 years: 25-50 mg every 4-6 hours; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Night-time sleep aid:",
"     </b>",
"     Oral: Children &ge;12 years: 50 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antitussive:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 to &lt;6 years: 6.25 mg every 4 hours; maximum: 37.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 to &lt;12 years: 12.5 mg every 4 hours; maximum: 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;12 years: 25 mg every 4 hours; maximum: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of dystonic reactions:",
"     </b>",
"     I.M., I.V.: 0.5-1 mg/kg/dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8082171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: 25 mg 2-3 times/day increasing as needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8082201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aler-Dryl: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AllerMax&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-Hist: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compoz&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Histaprin: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nytol&reg; Quick Caps: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simply Sleep&reg;: 25 mg [contains calcium 20 mg/caplet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sleep-ettes D: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sominex&reg; Maximum Strength: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twilite&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aler-Cap: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Allergy: 25 mg [contains calcium 35 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diphen: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diphenhist&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-dryl: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sleepinal&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; ZzzQuil&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Dye-Free Allergy: 25 mg [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compoz&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nytol&reg; Quick Gels: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unisom&reg; SleepGels&reg; Maximum Strength: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Captab, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diphenhist&reg;: 25 mg [contains calcium 45 mg/captab]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altaryl: 12.5 mg/5 mL (480 mL, 3840 mL) [ethanol free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade;: 12.5 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade;: 12.5 mg/5 mL (480 mL) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 50 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 50 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AllerMax&reg;: 12.5 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Allergy: 12.5 mg/5 mL (118 mL, 236 mL) [ethanol free; contains sodium 14 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Allergy Perfect Measure&trade;: 12.5 mg/5 mL (5 mL) [ethanol free; contains sodium 14 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Dye Free Allergy: 12.5 mg/5 mL (118 mL) [dye free, ethanol free, sugar free; contains sodium 11 mg/5 mL, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Siladryl Allergy: 12.5 mg/5 mL (118 mL, 237 mL, 473 mL) [ethanol free, sugar free; black-cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; ZzzQuil&trade;: 50 mg/30 mL (177 mL, 354 mL) [contains ethanol, propylene glycol, sodium 23 mg/30 mL, sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 12.5 mg/5 mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diphenhist&reg;: 12.5 mg/5 mL (118 mL, 473 mL) [ethanol free; contains sodium 7 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-dryl: 12.5 mg/5 mL (120 mL, 240 mL, 480 mL) [ethanol free; contains sodium 5 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Strip, orally disintegrating, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Allergy Quick Dissolve: 25 mg (10s) [contains sodium 4 mg/strip; vanilla-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Theraflu&reg; Thin Strips&reg; Multi Symptom: 25 mg (12s, 24s) [contains ethanol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PediaCare&reg; Children's Allergy: 12.5 mg/5 mL (118 mL) [contains sodium 14 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PediaCare&reg; Children's NightTime Cough: 12.5 mg/5 mL (118 mL) [ethanol free; contains sodium 15 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quenalin: 12.5 mg/5 mL (118 mL) [contains ethanol 5%, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silphen: 12.5 mg/5 mL (118 mL, 237 mL, 473 mL) [contains ethanol 5%; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aler-Tab: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Allergy: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-Dryl: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sleep-Tabs: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sominex&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally dissolving, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Allergy FastMelt&reg;: 12.5 mg [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Allergy FastMelt&reg;: 12.5 mg [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unisom&reg; SleepMelts&trade;: 25 mg [cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8082077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally-disintegrating tablet, strip",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8082174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When used to prevent motion sickness, first dose should be given 30 minutes prior to exposure. Injection solution is for I.V. or I.M. administration only; local necrosis may result with SubQ or intradermal use. For I.V. administration, inject at a rate &le;25 mg/minute.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8082130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, abciximab, aldesleukin, amifostine, amsacrine, argatroban, azithromycin, aztreonam, bivalirudin, caspofungin, ciprofloxacin, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doripenem, doxorubicin, doxorubicin liposome, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, gallium nitrate, gemcitabine, granisetron, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, idarubicin, linezolid, melphalan, meperidine, meropenem, methadone, methotrexate, morphine, ondansetron, oxaliplatin, paclitaxel, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, sargramostim, sufentanil, tacrolimus, teniposide, thiotepa, vinorelbine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, dexamethasone sodium phosphate, foscarnet, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, heparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, butorphanol, chlorpromazine, cimetidine, dimenhydrinate, droperidol, fentanyl, fluphenazine, glycopyrrolate, hydromorphone, hydroxyzine, iohexol, iopamidol, iothalamate meglumine, iothalamate meglumine 60%, iothalamate sodium 80%, lincomycin, meperidine, metoclopramide, midazolam, morphine, nalbuphine, pentazocine, prochlorperazine edisylate, promethazine, ranitidine, scopolamine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diatrizoate meglumine 52% and diatrizoate sodium 8%, furosemide, haloperidol, iodipamide meglumine, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, pantoprazole, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dexamethasone sodium phosphate, diatrizoate meglumine 52% and diatrizoate sodium 8%.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8082099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of allergic symptoms caused by histamine release including nasal allergies and allergic dermatosis; adjunct to epinephrine in the treatment of anaphylaxis; nighttime sleep aid; prevention or treatment of motion sickness; antitussive; management of Parkinsonian syndrome including drug-induced extrapyramidal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8082072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DiphenhydrAMINE may be confused with desipramine, dicyclomine, dimenhyDRINATE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benadryl&reg; may be confused with benazepril, Bentyl&reg;, Benylin&reg;, Caladryl&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sominex brand name for diphenhydramine [U.S., Canada], but also the brand name for promethazine [Great Britain]; valerian [Chile]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8082110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest tightness, extrasystoles, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, confusion, convulsion, disturbed coordination, dizziness, euphoria, excitation, fatigue, headache, insomnia, irritability, nervousness, paradoxical excitement, restlessness, sedation, sleepiness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menstrual irregularities (early menses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dry mucous membranes, epigastric distress, nausea, throat tightness, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuritis, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Labyrinthitis (acute), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal stuffiness, thickening of bronchial secretions, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic shock, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8082106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphenhydramine or any component of the formulation; acute asthma; neonates or premature infants; breast-feeding; use as a local anesthetic (injection)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8082107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Oral products: Avoid use of this potent anticholinergic agent due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age; tolerance develops to hypnotic effects; when used for severe allergic reaction, use may be appropriate (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Soy protein: Some preparations contain soy protein; avoid use in patients with soy protein or peanut allergies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Do not use with other products containing diphenhydramine, even ones used on the skin. Oral products are not for OTC use in children &lt;6 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8082118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8082101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8082102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Diphenhydramine crosses the placenta. Maternal diphenhydramine use has generally not resulted in an increased risk of birth defects; however, adverse events (withdrawal symptoms, respiratory depression) have been reported in newborns exposed to diphenhydramine",
"     <i>",
"      in utero",
"     </i>",
"     . Antihistamines are recommended for the treatment of rhinitis, urticaria, and pruritus with rash in pregnant women (although second generation antihistamines may be preferred). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8082104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8082105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diphenhydramine is excreted into breast milk; drowsiness has been reported in a breast-feeding infant. Premature infants and newborns have a higher risk of intolerance to antihistamines. Breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8082173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium and/or phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8082205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Banophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $2.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Benadryl Dye-Free Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $4.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Benadryl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $4.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (DiphenhydrAMINE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $5.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $8.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (ZzzQuil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $7.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Benadryl Allergy Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (18): $5.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (DiphenhydrAMINE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg/5 mL (5 mL): $0.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Medi-Phedryl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg/5 mL (120 mL): $3.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Banophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg/5 mL (118 mL): $2.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Benadryl Allergy Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg/5 mL (118 mL): $5.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Benadryl Readymist External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-0.1% (7.7 mL): $4.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (PediaCare Childrens Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg/5 mL (118 mL): $5.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Scot-Tussin Allergy Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg/5 mL (240 mL): $6.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (ZzzQuil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/30 mL (177 mL): $4.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DiphenhydrAMINE HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (1 mL): $1.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strip",
"     </b>",
"     (Benadryl Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (10): $4.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strip",
"     </b>",
"     (Theraflu Multi Symptom Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (12): $4.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strip",
"     </b>",
"     (Triaminic Cough/Runny Nose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (14): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Alka-Seltzer Plus Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $3.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Banophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $1.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Benadryl Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (48): $7.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Benadryl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $12.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (DiphenhydrAMINE HCl (Sleep) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (50): $2.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (DiphenhydrAMINE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $3.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (50): $4.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nytol Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (8): $3.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nytol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (16): $3.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Simply Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $2.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Simply Sleep Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $10.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sominex Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (16): $4.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8082178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms, mental alertness",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aliserin (IT);",
"     </li>",
"     <li>",
"      Allermin (JP);",
"     </li>",
"     <li>",
"      Beanamine (SG);",
"     </li>",
"     <li>",
"      Bena (HK);",
"     </li>",
"     <li>",
"      Benadryl (AR, CO, EC, GR, IN, MY, PH, PK, TH, VE);",
"     </li>",
"     <li>",
"      Benadryl A (UY);",
"     </li>",
"     <li>",
"      Benadryl Allergy (PE);",
"     </li>",
"     <li>",
"      Benadryl for the Family Original (AU);",
"     </li>",
"     <li>",
"      Benamine (TW);",
"     </li>",
"     <li>",
"      Bendol (HK);",
"     </li>",
"     <li>",
"      Benocten (CH);",
"     </li>",
"     <li>",
"      Benylan (DK);",
"     </li>",
"     <li>",
"      Bexil (PH);",
"     </li>",
"     <li>",
"      Broncho D (IL);",
"     </li>",
"     <li>",
"      Calm U (NZ);",
"     </li>",
"     <li>",
"      Calmaben (BG);",
"     </li>",
"     <li>",
"      Cerylana (VE);",
"     </li>",
"     <li>",
"      Desentol (SE);",
"     </li>",
"     <li>",
"      Diamine (TW);",
"     </li>",
"     <li>",
"      DiBendryl (TH);",
"     </li>",
"     <li>",
"      Dibrondrin (AT);",
"     </li>",
"     <li>",
"      Difenidrin (BR);",
"     </li>",
"     <li>",
"      Dormutil (DE);",
"     </li>",
"     <li>",
"      Dormutil N (NO);",
"     </li>",
"     <li>",
"      Histergan (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Hydramine (TW);",
"     </li>",
"     <li>",
"      Nardyl (DE);",
"     </li>",
"     <li>",
"      Nytol (IL);",
"     </li>",
"     <li>",
"      Otede (ID);",
"     </li>",
"     <li>",
"      R Calm (BE);",
"     </li>",
"     <li>",
"      Rabaphen (PH);",
"     </li>",
"     <li>",
"      Resmin (JP);",
"     </li>",
"     <li>",
"      Sleepeze-PM (ZA);",
"     </li>",
"     <li>",
"      Snuzaid (AU);",
"     </li>",
"     <li>",
"      Somol (CN);",
"     </li>",
"     <li>",
"      Soniphen (PH);",
"     </li>",
"     <li>",
"      Unisom Sleepgels (AU, NZ);",
"     </li>",
"     <li>",
"      Valdres (ID);",
"     </li>",
"     <li>",
"      Vena (JP);",
"     </li>",
"     <li>",
"      Venasmin (JP);",
"     </li>",
"     <li>",
"      Vivinox (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8082131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract; anticholinergic and sedative effects are also seen",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8082134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Histamine-induced wheal suppression: &le;10 hours (Simons, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Histamine-induced flare suppression: &le;12 hours (Simons, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 22 L/kg (range: 15-28 L/kg); Adults: 17 L/kg (range: 13-20 L/kg); Elderly: 14 L/kg (range: 7-20 L/kg) (Blyden, 1986; Simons, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98.5% (Vozeh, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic n-demethylation via CYP2D6; minor demethylation via  CYP1A2, 2C9 and 2C19; smaller degrees in pulmonary and renal systems; significant first-pass effect (Akutsu, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 42% to 62% (Paton, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children: 5 hours (range: 4-7 hours); Adults: 9 hours (range: 7-12 hours); Elderly: 13.5 hours (range: 9-18 hours) (Blyden, 1986; Simons, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~2 hours (Blyden, 1986; Simons, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites and unchanged drug) (Albert, 1975; Maurer, 1988)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG (American College of Obstetricians and Gynecologists), \"Practice Bulletin: Nausea and Vomiting of Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 103(4):803-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/15051578/pubmed\" id=\"15051578\" target=\"_blank\">",
"        15051578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Akutsu T, Kobayashi K, Sakurada K, et al, \"Identification of Human Cytochrome P450 Isozymes Involved in Diphenhydramine N-Demethylation,\"",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2007, 35(1):72-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/17020955/pubmed\" id=\"17020955\" target=\"_blank\">",
"        17020955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Albert KS, Hallmark MR, Sakmar E, et al, \"Pharmacokinetics of DIphenhydramine in Man,\"",
"      <i>",
"       J Pharmacokinet Biopharm",
"      </i>",
"      , 1975, 3(3):159-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/1159620/pubmed\" id=\"1159620\" target=\"_blank\">",
"        1159620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Becker DE, \"Management of Immediate Allergic Reactions,\"",
"      <i>",
"       Dent Clin North Am",
"      </i>",
"      , 1995, 39(3):577-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/7556791/pubmed\" id=\"7556791\" target=\"_blank\">",
"        7556791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blyden GT, Greenblatt DJ, Scavone JM, et al, \"Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous and Oral Administration,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1986, 26(7):529-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/3760245/pubmed\" id=\"3760245\" target=\"_blank\">",
"        3760245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corre KA, Niemann JT, Bessen HA, et al, \"Extended Therapy for Acute Dystonic Reactions,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1984, 13(3):194:7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/6696308/pubmed\" id=\"6696308\" target=\"_blank\">",
"        6696308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doenecke AL and Heuermann RC, \"Treatment of Haloperidol Abuse With Diphenhydramine,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1980, 137(4):487-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/7361941/pubmed\" id=\"7361941\" target=\"_blank\">",
"        7361941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eigenmann, PA, Burks, AW, Bannon GA, et al, \"Identification of Unique Peanut and Soy Allergens in Sera Adsorbed With Cross-Reacting Antibodies,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1996, 98 (5 Pt 1):969-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/8939161/pubmed\" id=\"8939161\" target=\"_blank\">",
"        8939161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garnett WR, \"Diphenhydramine,\"",
"      <i>",
"       Am Pharm",
"      </i>",
"      , 1986, NS26(2):35-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelner MJ, \"Positive Diphenhydramine Interference in the EMIT-D.A.U. Assay,\"",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1984, 30(8):1430.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/6378429/pubmed\" id=\"6378429\" target=\"_blank\">",
"        6378429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine BS and Smith ML, \"Effects of Diphenhydramine on Immunoassays of Phencyclidine in Urine,\"",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1990, 36(6):1258.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/2357810/pubmed\" id=\"2357810\" target=\"_blank\">",
"        2357810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindsay CA, Williams GD, and Levin DL, \"Fatal Adult Respiratory Distress Syndrome After Diphenhydramine Toxicity in a Child: A Case Report,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(4):777-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/7712771/pubmed\" id=\"7712771\" target=\"_blank\">",
"        7712771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maurer H and Pfleger K, \"Screening Procedure for the Detection of Alkanolamine Antihistamines and Their Metabolites in Urine Using Computerized Gas Chromatography-Mass Spectrometry,\"",
"      <i>",
"       J Chromatogr",
"      </i>",
"      , 1988, 428(1):43-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/2902103/pubmed\" id=\"2902103\" target=\"_blank\">",
"        2902103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller AA, \"Diphenhydramine Toxicity in a Newborn: A Case Report,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2000, 20(6):390-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/11002881/pubmed\" id=\"11002881\" target=\"_blank\">",
"        11002881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parkin DE, \"Probable Benadryl Withdrawal Manifestations in a Newborn Infant,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1974, 85(4):580.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/4443870/pubmed\" id=\"4443870\" target=\"_blank\">",
"        4443870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paton DM and Webster DR, \"Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines),\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1985, 10(6):477-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/2866055/pubmed\" id=\"2866055\" target=\"_blank\">",
"        2866055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sampson HA, Munoz-Furtong A, Campbell RL, et al, \"Second Symposium on the Definition and Management of Anaphylaxis: Summary Report &minus; Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2006, 7(4):373-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/16546624 /pubmed\" id=\"16546624 \" target=\"_blank\">",
"        16546624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saxen I, \"Letter: Cleft Palate and Maternal Diphenhydramine Intake,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1974, 1(7854):407-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/4131054/pubmed\" id=\"4131054\" target=\"_blank\">",
"        4131054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seto A, Einarson T, and Koren G, \"Pregnancy Outcome Following First Trimester Exposure to Antihistamines: Meta-Analysis,\"",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 1997, 14(3):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/9259911/pubmed\" id=\"9259911\" target=\"_blank\">",
"        9259911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons KJ, Watson WT, Martin TJ, et al, \"Diphenhydramine: Pharmacokinetics and Pharmacodynamics in Elderly Adults, Young Adults, and Children,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1990, 30(7):665-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/2391399/pubmed\" id=\"2391399\" target=\"_blank\">",
"        2391399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sorisky A and Watson DC, \"Positive Diphenhydramine Interference in the EMIT-ST Assay for Tricyclic Antidepressants in the Serum,\"",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1986, 32(4):715.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/3513997/pubmed\" id=\"3513997\" target=\"_blank\">",
"        3513997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sridhar KS and Donnelly E, \"Combination Antiemetics for Cisplatin Chemotherapy,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 1988, 61(8):1508-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/3280112/pubmed\" id=\"3280112\" target=\"_blank\">",
"        3280112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stancavage M, Osterhoudt KC, and Henretig FM, \"Caladryl Ingestion: A New Poisoning From a Common Household Product,\"",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):520.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsavaris N, Zamanis N, Zinelis A, et al, \"Diphenhydramine for Nausea and Vomiting Related to Cancer Chemotherapy With Cisplatin,\"",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 1991, 6(8):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/33/7705/abstract-text/1955741/pubmed\" id=\"1955741\" target=\"_blank\">",
"        1955741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weston MV, \"Lovelorn and Snakebite,\"",
"      <i>",
"       Hosp Pract (Off Ed)",
"      </i>",
"      , 1986, 21(3A):140-3.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9109 Version 55.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7705=[""].join("\n");
var outline_f7_33_7705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082074\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082075\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082507\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082170\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082169\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082171\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082201\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082077\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082174\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082130\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082099\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082072\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082110\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082106\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082107\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082113\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082114\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082118\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082101\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082102\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082104\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082105\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082173\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082205\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082178\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962013\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082131\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082134\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9109|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=related_link\">",
"      Diphenhydramine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/48/19207?source=related_link\">",
"      Diphenhydramine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1269?source=related_link\">",
"      Diphenhydramine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/10/4260?source=related_link\">",
"      Diphenhydramine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/51/13108?source=related_link\">",
"      Diphenhydramine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_33_7706="Assessment of rheumatoid arthritis activity in clinical trials and clinical practice";
var content_f7_33_7706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/33/7706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/33/7706/contributors\">",
"     Josef S Smolen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/33/7706/contributors\">",
"     Daniel Aletaha, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/33/7706/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/33/7706/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/33/7706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/33/7706/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/33/7706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7360969\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to the management of rheumatoid arthritis (RA) have evolved as an increasing number of effective disease-modifying anti-rheumatic drugs (DMARDs) have become available. The early introduction of DMARDs has become standard of care, and depends upon early diagnosis",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/1\">",
"     1",
"    </a>",
"    ]. Such early diagnosis is facilitated by the 2010 American College of",
"    <span class=\"nowrap\">",
"     Rheumatology/European",
"    </span>",
"    League Against Rheumatism rheumatoid arthritis classification criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of DMARD use are not only to ameliorate the symptoms and signs of active RA, but also to prevent structural joint damage and avoid functional impairment. The development of new antirheumatic therapies, including biologic agents targeted against specific components of the immune system, has required the availability of instruments that permit the assessment of disease activity and the response to therapy. Regardless of whether patients are evaluated in the context of a clinical trial or longitudinal clinical practice, the successful application of DMARD therapy requires that the goals of therapy be specified in advance and that the specific choice of DMARDs be revisited on a regular basis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical indicators employed in the assessment of RA activity are discussed here. The roles of both individual variables (eg, swollen joint counts and acute phase reactant measurements) and composite indices for disease activity assessment are considered, as are definitions of remission and criteria for clinically significant responses. Although much of the discussion centers on clinical trial outcome measures, we also provide recommendations for clinical practice.",
"   </p>",
"   <p>",
"    A number of other topic reviews are related to the discussion of RA disease activity and complement the information provided here. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical features of RA, including the importance of distinguishing disease activity from structural joint damage are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"       \"Clinical features of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Functional capacity and functional disability indices, which relate to a large extent to the degree of RA disease activity, are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link\">",
"       \"Disease outcome and functional capacity in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Descriptions of a variety of biologic markers of disease activity, including those with established clinical utility and those that are of investigational interest are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2234?source=see_link\">",
"       \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of RA, including pharmacologic and nonpharmacologic as well as surgical interventions is surveyed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"       \"General principles of management of rheumatoid arthritis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link\">",
"       \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7360976\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conceptual framework for the assessment of disease activity in RA is defined by several principles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active RA leads to severe joint destruction, functional disability, and impaired health status [",
"      <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/5-12\">",
"       5-12",
"      </a>",
"      ], particularly if sustained at high levels for prolonged periods of time. Thus, reduction of clinical disease activity through prudent DMARD use is an essential therapeutic aim.",
"     </li>",
"     <li>",
"      Functional impairment may relate to both active RA, manifested by symptoms such as pain, swelling, and stiffness of the joints, and to structural joint damage occurring as the consequence of previously active disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/7,9,13-15\">",
"       7,9,13-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With few exceptions",
"      <strong>",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/16\">",
"       16",
"      </a>",
"      ], clinically active RA and the processes leading to joint destruction are linked, such that damage usually progresses in the presence of active disease",
"      <strong>",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/16-23\">",
"       16-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Monitoring disease activity at regular, short-term intervals (not to exceed three months) and appropriate modifications of DMARD therapy to establish and maintain control of disease result in improved radiographic and functional outcomes in patients with RA",
"      <strong>",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. To this end, the 2010 EULAR recommendations on the management of RA provide a treatment strategy, including recommendations for an approach to the institution of various therapeutic agents",
"      <strong>",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Therapeutic goals are the achievement of remission (ie, the virtual absence of disease activity) or the lowest possible state of disease activity. These goals are consistent with the recommendations of an international task force [",
"      <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/4\">",
"       4",
"      </a>",
"      ]. In the majority of RA patients, the achievement of sustained disease remission corresponds to the cessation of joint damage [",
"      <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/8,18,27,28\">",
"       8,18,27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections describe individual elements that are assessed in order to determine RA activity, the concepts of composite indices and response criteria, and the definitions of low disease activity and remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7360983\">",
"    <span class=\"h1\">",
"     INDIVIDUAL VARIABLES OF DISEASE ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common indicators of disease activity in RA include the following measurements (reviewed in [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/29\">",
"     29",
"    </a>",
"    ]):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Swollen and tender joint counts",
"     </li>",
"     <li>",
"      Pain",
"     </li>",
"     <li>",
"      Patient and evaluator global assessments of disease activity",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate and C-reactive protein (ESR, CRP)",
"     </li>",
"     <li>",
"      Duration of morning stiffness",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional measures, which partly reflect disease activity and partly reflect disease outcome, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measures of function (eg, the Health Assessment Questionnaire)",
"     </li>",
"     <li>",
"      Health status measures (eg, the Short Form 36)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7360990\">",
"    <span class=\"h2\">",
"     Core sets of disease activity variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning in the 1990s, several groups defined core sets of disease activity variables. The American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), and a group of investigators representing both the World Health Organization (WHO) and International League of Associations of Rheumatology (ILAR) all published similar core sets of activity variables [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The methods used to identify these variables were driven by clinical data and met several criteria for validity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All three core sets include swollen and tender joint counts, patient assessment of pain, patient global assessment of disease activity, and a measure of the acute phase response. As an example, the ACR core data set includes a total of seven measures: three performed by the evaluator (swollen joint count, tender joint count, and global assessment of disease activity); three collected by patient self-report (functional status, pain, and global assessment of disease activity); and a laboratory measure (either an ESR or CRP). The ACR and",
"    <span class=\"nowrap\">",
"     WHO/ILAR",
"    </span>",
"    core sets both include evaluator global assessments of disease activity and physical function. In contrast, in the EULAR core set, physical function is regarded as an outcome variable rather than a process variable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7360997\">",
"    <span class=\"h2\">",
"     Swollen and tender joint counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joints are typically assessed according to two characteristics: 1) soft tissue swelling and effusion (the swollen joint count); and, 2) pain on pressure or motion (the tender joint count). In general, neither the weighting of joints by their size (ie, the cartilage surface area) nor grading them by degree of swelling or tenderness confers validity and reliability [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 28 joint count has become a standard for use in both clinical practice and clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. The 28 joint count excludes assessments of the foot and ankle joints, because the interpretation of swelling and tenderness in these joints is confounded frequently by disorders other than RA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/37,39,40\">",
"     37,39,40",
"    </a>",
"    ]. Although the 28 joint count has been criticized for leaving out assessment of the feet, it has been thoroughly validated and employed reliably in clinical trials and other analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. It is the basis of today&rsquo;s most frequently employed composite measures of disease activity. Importantly, employing a 28-joint count for determining levels of disease activity and response does not obviate the responsibility to also assess ankles and feet in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361004\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is usually measured by visual analog scales [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/40-42\">",
"     40-42",
"    </a>",
"    ], which most often use horizontal 100 mm lines. Patients indicate their degree of pain (typically over the preceding week) by placing a mark between \"no pain\" (left end, 0 mm) and excruciating pain (right end, 100 mm). Alternatives to visual analog scales include numerical rating scales (ranging from 0 to 10 in steps of 1 or 0.5) and categorical scales (eg, 5-point Likert scales), both of which are also reliable and sensitive to change [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361011\">",
"    <span class=\"h2\">",
"     Patient and evaluator global assessments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Global disease activity rated by the patient, the evaluator, or both (and termed, respectively, the PGA or EGA, as appropriate) is assessed in a similar manner using visual analog scales, numerical rating scales, or Likert scales. Measuring the PGA acknowledges the importance of patient-reported outcomes. Whereas the EGA typically integrates information from both subjective and objective variables, the PGA is considered a subjective measure. Because patients are more likely than are medically-trained evaluators to construe functional disability as a manifestation of active disease and because medically-trained evaluators have greater context for comparison with other RA patients, PGAs are usually scored at higher levels than are EGAs.",
"   </p>",
"   <p>",
"    The typical question asked of the patient for a PGA is: \"Considering all the ways your arthritis has affected you, how do you feel your arthritis is today?\" This assessment is presumed to also take into account aspects of disease activity that might be less well appreciated by the physician (eg, fatigue or sleep disturbances).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361018\">",
"    <span class=\"h2\">",
"     Acute phase reactants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute phase reactant levels, particularly the ESR and CRP, constitute the most objective disease activity measures. Acute phase reactant levels correlate well with both clinical disease activity measurements and radiographic progression of joint damage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/6,10,46-49\">",
"     6,10,46-49",
"    </a>",
"    ]. The ESR and CRP are the two biomarkers used most widely to assess disease activity. These tests are widely available, relatively inexpensive, reflective of the cascade of inflammatory events associated with active RA, and the CRP in particular is well standardized. Measurements of individual components of this response, e.g., levels of the interleukin (IL)-1 beta, IL-6, or TNF-alpha, are not more useful in assessing RA activity and are prone to greater variation from laboratory to laboratory. Moreover, among these cytokines, only IL-6 can be consistently and reliably measured in patient sera.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361025\">",
"    <span class=\"h2\">",
"     Other variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other variables associated with disease activity include the duration of morning stiffness, degree of fatigue, and the reduction in functional capacity. Morning stiffness",
"    <strong>",
"    </strong>",
"    is not contained among the core set variables because of its higher variability and lower sensitivity to change compared to other measures. A variety of patient-reported instruments are available to measure levels of fatigue, including the",
"    <span class=\"nowrap\">",
"     vitality/fatigue",
"    </span>",
"    scales that constitute part of the SF-36. More commonly, however, fatigue is assessed simply through the use of a visual analog scale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361032\">",
"    <span class=\"h1\">",
"     COMPOSITE INDICES FOR DISEASE ACTIVITY ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The individual variables outlined above reflect major characteristics of the disease within the population of RA patients as a whole. Given the heterogeneity of RA, however, the predominance of these indicators may be highly variable across individual patients, and may even vary with time within individual patients. As a result, the evaluation of a single core variable (eg, the ESR) in patients with RA would not reflect accurately the full spectrum of the disease. In addition, the evaluation of all variables within core sets often leads to heterogeneous responses and substantial methodological problems [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/33-35,50\">",
"     33-35,50",
"    </a>",
"    ]. Thus, \"composite\" indices combining several core set variables have been developed. Several composite indices are in common use (",
"    <a class=\"graphic graphic_table graphicRef75446 \" href=\"UTD.htm?28/40/29325\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Formulas for calculating the indices vary in complexity, some are challenging to compute [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/10,38,51-54\">",
"     10,38,51-54",
"    </a>",
"    ]. The",
"    <strong>",
"     D",
"    </strong>",
"    isease",
"    <strong>",
"     A",
"    </strong>",
"    ctivity",
"    <strong>",
"     S",
"    </strong>",
"    core (DAS), its derivative (the DAS28), the",
"    <strong>",
"     S",
"    </strong>",
"    implified",
"    <strong>",
"     D",
"    </strong>",
"    isease",
"    <strong>",
"     A",
"    </strong>",
"    ctivit",
"    <strong>",
"     y I",
"    </strong>",
"    ndex (SDAI), and the",
"    <strong>",
"     C",
"    </strong>",
"    linical",
"    <strong>",
"     D",
"    </strong>",
"    isease",
"    <strong>",
"     A",
"    </strong>",
"    ctivity",
"    <strong>",
"     I",
"    </strong>",
"    ndex (CDAI) are described in greater detail below. Interestingly, baseline disease activity by these composite scores, and especially disease activity after three months of therapy with DMARDs is highly predictive of disease activity at later points in time (one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/55\">",
"     55",
"    </a>",
"    ] allowing to adopt treatment strategies that allow rapid, dynamic changes of therapeutic agents in patients who continue with high (or sometimes moderate) disease activity by three to six months from start of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361039\">",
"    <span class=\"h2\">",
"     Disease activity score (DAS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basis of the DAS was the clinician's decision to raise or lower DMARD doses based on a largely qualitative assessment of disease activity and reflected clinical practice in about 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/51\">",
"     51",
"    </a>",
"    ]. Several features make the DAS challenging to use in clinical trial and practice settings. First, the DAS employs the Ritchie Articular Index [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/52\">",
"     52",
"    </a>",
"    ], a measure with major shortcomings in terms of feasibility and reliability, to evaluate joint tenderness. Second, the DAS employs an extensive 44 joint count to record the number of swollen joints. Finally, once the data required to complete the DAS are accumulated, the formula for calculating the score is quite complex, using different weights for each of the variables as well as square roots or logarithmic transformations in the case of some (",
"    <a class=\"graphic graphic_table graphicRef75446 \" href=\"UTD.htm?28/40/29325\">",
"     table 1",
"    </a>",
"    ). In summary, the original DAS is complicated and not very user friendly, and therefore not ideally suited to wide use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361046\">",
"    <span class=\"h3\">",
"     DAS28 score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of the DAS was important because it provided a global summative and continuous score for disease activity assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/51\">",
"     51",
"    </a>",
"    ]. A modification of the DAS, the DAS28, is considerably more practical. The DAS28 eliminated the grading of joints and reduced the number of joints evaluated to 28 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/38,54\">",
"     38,54",
"    </a>",
"    ]; it has largely replaced the traditional DAS in clinical trials and in practice. A calculator for the DAS28 is available (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?13/36/13894?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ranges of DAS28 scores that correspond to high, moderate, low disease activity, and remission have been proposed (",
"    <a class=\"graphic graphic_table graphicRef75446 \" href=\"UTD.htm?28/40/29325\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62663 \" href=\"UTD.htm?36/1/36894\">",
"     figure 1",
"    </a>",
"    ). High disease activity relates to DAS28 &gt;5.1, moderate to DAS28 of &gt;3.2 to 5.1, low disease activity is regarded in the range of 2.6 to 3.2, and remission &lt;2.6. It should be noted that nearly 15 percent of patients with DAS28 scores of 2.6 (the cutpoint for remission) continue to have at least two swollen joints; some may have more than 10 swollen joints yet still be categorized as in \"remission\" using this composite index [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/11,56-58\">",
"     11,56-58",
"    </a>",
"    ]. Other composite measures also permit a number of inflamed joints among patients who fulfill criteria for remission.",
"   </p>",
"   <p>",
"    One characteristic of the DAS28 is the greater relative weight it gives to measures of the acute phase response. This can result in a disproportionately lower estimate of disease activity compared with other measures, such as the SDAI or CDAI (see below) when used to assess disease activity in patients receiving agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    that have more pronounced effects on acute phase reactants relative to their overall clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/59\">",
"     59",
"    </a>",
"    ]. As revealed by the formula of the DAS28, it also gives half as much weight to a swollen joint as it does to a tender joint, although both have a similar level of severity of inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361060\">",
"    <span class=\"h2\">",
"     Simplified disease activity index (SDAI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SDAI, which employs five of the core set variables (",
"    <a class=\"graphic graphic_table graphicRef75446 \" href=\"UTD.htm?28/40/29325\">",
"     table 1",
"    </a>",
"    ) is calculated using a linear sum of unweighted, untransformed variables [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SDAI is defined as the simple sum of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tender joint count (using 28 joints)",
"     </li>",
"     <li>",
"      Swollen joint count (using 28 joints)",
"     </li>",
"     <li>",
"      Patient global assessment (0 to 10 scale)",
"     </li>",
"     <li>",
"      Physician global assessment (0 to 10 scale)",
"     </li>",
"     <li>",
"      C-reactive protein level",
"      <span class=\"nowrap\">",
"       (mg/dL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The SDAI has been validated for use in both clinical trials and clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/11,60,61\">",
"     11,60,61",
"    </a>",
"    ]. Moreover, it has been shown to have the highest sensitivity and specificity for predicting physicians' decisions to change DMARD therapy in 2005 when compared to other composite scores [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A calculator for the SDAI is available, although the SDAI (and the CDAI, see below) can potentially be performed without the use of a calculator in daily practice (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?38/51/39733?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cutpoints have been established for the various activity states (",
"    <a class=\"graphic graphic_table graphicRef75446 \" href=\"UTD.htm?28/40/29325\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62663 \" href=\"UTD.htm?36/1/36894\">",
"     figure 1",
"    </a>",
"    ). A cutpoint of 15 for the SDAI had the best combination of sensitivity and specificity (90 percent and 86 percent, respectively) when compared to the treating physicians' decisions to change DMARDs because of active disease in a more recent observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/61\">",
"     61",
"    </a>",
"    ]. The cutpoint for remission, an SDAI of &le;3.3, does not allow the presence of more than two joints that are swollen or tender; because of its stringency, it also constitutes the index-based ACR-EULAR remission definition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The established cutpoints of 11 and 26 separate low disease activity (&le;11) from moderate (&le;26) and high (&gt;26) disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/11,65\">",
"     11,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361067\">",
"    <span class=\"h2\">",
"     Clinical disease activity index (CDAI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A further simplification of the SDAI, the CDAI, does not require the measurement of an acute phase reactant, but otherwise uses the same measures as the SDAI (",
"    <a class=\"graphic graphic_table graphicRef75446 \" href=\"UTD.htm?28/40/29325\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62663 \" href=\"UTD.htm?36/1/36894\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7361060\">",
"     'Simplified disease activity index (SDAI)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The CDAI correlates well with other disease activity scores and response criteria, as well as with progression of joint damage and functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/10,54,65\">",
"     10,54,65",
"    </a>",
"    ]. The advantage of the CDAI is that it facilitates immediate treatment decisions based entirely on clinical criteria and includes assessment of the joints, the principle &ldquo;target organ\" in RA. This attribute is useful in clinical trials and practice, since it circumvents the potential problem of lab to lab variation in the measurement of acute phase reactants. A calculator for the CDAI is available (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?26/36/27205?source=see_link\">",
"     calculator 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361074\">",
"    <span class=\"h1\">",
"     PHYSICAL FUNCTION ASSESSMENTS AS MEASURES OF DISEASE ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because active RA exerts a substantial effect on physical function, instruments designed to measure physical function are also useful indicators of disease activity. Such instruments, developed for generic use, are employed commonly in clinical trials, less often in clinical practice. The two physical function assessment tools used most frequently are the Health Assessment Questionnaire (HAQ) and the Medical Outcomes Study Short Form-36 (SF-36) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/66-69\">",
"     66-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361081\">",
"    <span class=\"h2\">",
"     Health Assessment Questionnaire (HAQ)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete HAQ is a comprehensive instrument designed to assess patient disability, discomfort, medication side effects, costs, and mortality. Of these components, only the HAQ Disability Index (HAQ-DI) is used frequently in clinical trials and clinical practice. The HAQ-DI, a component of the ACR core data set for the evaluation of RA disease activity and outcome, evaluates patients' ability to perform activities of daily living through their answers to 20 questions designed to assess upper or lower extremity use. These questions are organized into eight categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each question is answered on a four-level scale of impairment ranging from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; and 3 = inability to do.",
"   </p>",
"   <p>",
"    The final HAQ index, which ranges from 0 to 3, is the mean of scores from all eight categories. HAQ scores &lt;0.3 are considered normal, however, the mean HAQ of the population rises with age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/70\">",
"     70",
"    </a>",
"    ]. Higher HAQ scores indicate increasing disability. The minimal clinically important difference in serial HAQ scores has been suggested to be 0.22 on the group level. Several modifications of the HAQ have been employed in clinical trials and practice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the primary influence on the HAQ is disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/9,67\">",
"     9,67",
"    </a>",
"    ], the score reflects both joint damage and disease activity. Therefore, results of the HAQ require careful interpretation when used for disease activity assessment, as",
"    <strong>",
"    </strong>",
"    the irreversible, damage-related component of disability as assessed by HAQ increases with the degree of joint damage and with disease duration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Thus, it has been proposed that the activity-related HAQ (ACT-HAQ) should be distinguished from its damage-related component (DAM-HAQ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361088\">",
"    <span class=\"h2\">",
"     The short form-36",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short form (SF)-36 is a patient-reported instrument designed to assess overall health status; it is not disease-specific [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/69\">",
"     69",
"    </a>",
"    ]. The SF-36, usually utilized to measure patients' quality of life, has been validated in numerous diseases, including RA. The instrument consists of 36 questions organized into 8 domains: physical function, physical role, general health, bodily pain, mental health, social function,",
"    <span class=\"nowrap\">",
"     vitality/fatigue,",
"    </span>",
"    and emotional role. Data from these eight domains can be summarized into two categories, a physical component score and a mental component score. SF-36 results are particularly useful for comparing quality of life across cohorts of patients with different diseases, but also correlate well with other measures of RA activity. Increasing SF-36 scores are indicative of improving health status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361095\">",
"    <span class=\"h1\">",
"     PATIENT-REPORTED INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several self-reported instruments are available for the assessment of RA activity. These include the",
"    <strong>",
"     R",
"    </strong>",
"    heumatoid",
"    <strong>",
"     A",
"    </strong>",
"    rthritis",
"    <strong>",
"     D",
"    </strong>",
"    isease",
"    <strong>",
"     A",
"    </strong>",
"    ctivity",
"    <strong>",
"     I",
"    </strong>",
"    ndex (RADAI), the",
"    <strong>",
"     R",
"    </strong>",
"    apid",
"    <strong>",
"     A",
"    </strong>",
"    ssessment",
"    <strong>",
"    </strong>",
"    of",
"    <strong>",
"     D",
"    </strong>",
"    isease",
"    <strong>",
"     A",
"    </strong>",
"    ctivity in",
"    <strong>",
"     R",
"    </strong>",
"    heumatology (RADAR), and a modification of the",
"    <strong>",
"     R",
"    </strong>",
"    outine",
"    <strong>",
"     A",
"    </strong>",
"    ssessment of",
"    <strong>",
"     P",
"    </strong>",
"    atient",
"    <strong>",
"     I",
"    </strong>",
"    ndex",
"    <strong>",
"     D",
"    </strong>",
"    ata (RAPID3) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32342639\">",
"    <span class=\"h2\">",
"     RADAI and RADAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RADAI encompasses five items, including patient-assessed joint counts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/71\">",
"     71",
"    </a>",
"    ]. A major detraction of the RADAI, similar to that of the DAS, is the need for a calculator. In contrast, the RADAR is a brief, two-page questionnaire that includes six items related to arthritis symptoms, physical function, work impact, psychological status, social health, and satisfaction with health status [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/72\">",
"     72",
"    </a>",
"    ]. Although the use of patient-reported indices of disease activity such as the RADAI or RADAR is appealing in RA, a condition associated with large personal dimensions, these instruments are rarely used in clinical trials and almost never in clinical practice. The patient-reported instruments used most often in clinical trials are global assessments of disease activity (eg, visual analog scales), HAQ scores, and the SF-36.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32342654\">",
"    <span class=\"h2\">",
"     RAPID3 score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RAPID3, as an expansion of the RAPID, constitutes an index that is based upon patient self-reported outcomes only and is simple to administer. It includes the HAQ, physical function, pain, and patient global estimate, all normalized to 0-10, counted together, and divided by 3 to yield a score on a scale of 0-10",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    It does not require a formal joint count, although swollen joint counts correlate with progression of joint damage",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. It does provide similar quantitative information to the DAS28 or the CDAI regarding disease activity",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361102\">",
"    <span class=\"h1\">",
"     RESPONSE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response criteria, defined for both moderate and major changes in disease activity, have been developed for all of the major RA activity assessment indices. Such criteria can be applied to large numbers of patients in the context of clinical trials, and also in gauging the treatment responses of individual patients over time. Response criteria may involve either the comparison of a patient's activity score to a baseline value for that same patient, or the achievement of a certain disease activity state (eg, either remission or low disease activity).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361109\">",
"    <span class=\"h2\">",
"     ACR response criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early attempt to define minimal response requirements was provided by the Paulus criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/75\">",
"     75",
"    </a>",
"    ]. These criteria formed the basis for the ACR response criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/76\">",
"     76",
"    </a>",
"    ], which (in their initial iteration) outlined the variables of a 20 percent improvement. The ACR20 response, a standard measure for many clinical trials performed since 1995, is defined as improvement of at least 20 percent in the number of both swollen and tender joints, as well as at least 20 percent improvement in three or more of the five remaining core set variables (",
"    <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The categorical response criteria embodied in the ACR20, ACR50, and ACR70 measure the frequency of benefit (ie, the proportion of patients receiving a certain treatment that achieve a defined response). In contrast, measuring the mean or median ACR-N improvement facilitates an estimation of the cumulative magnitude of benefit that may be anticipated for a typical patient relative to the baseline disease activity. Both types of measures are useful for certain situations, and in many cases the information they provide are complementary. The hybrid-ACR response requires further validation. These measures are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361116\">",
"    <span class=\"h3\">",
"     ACR20 response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACR20 response discriminates accurately between the effects of active medications and those of placebo. However, because of improvements in RA treatment, the ACR20 is no longer considered an optimal measure of clinically meaningful change: patients who achieve only ACR20 responses may still have substantial disease burdens from active RA. Moreover, the ACR20 has other potential weaknesses in some applications: 1) it does not measure directly any responses &gt;20 percent in magnitude over baseline; 2) it characterizes the percentage of patients who meet this cutoff, rather than the response of the average patient; 3) it measures the change in patients' disease activity compared with baseline, but does not quantify disease activity at the end of the period of interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361123\">",
"    <span class=\"h3\">",
"     ACR50 and ACR70 responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;More ambitious criteria for improvements in disease activity have been proposed; namely, the ACR50 and ACR70 responses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/77\">",
"     77",
"    </a>",
"    ], corresponding to 50 and 70 percent improvements, respectively. In contrast to ACR20 responses, patients notice dramatic differences following the achievement of ACR50 and ACR70 responses. In clinical trials of biologic agents, DMARDs, or various combinations, the percentage of patients achieving ACR20, 50, and 70 responses with the study agent (or combination of agents) have been on the order of 40 to 80 percent, 25 to 60 percent, and 10 to 40 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361130\">",
"    <span class=\"h3\">",
"     ACR-N response",
"    </span>",
"    &nbsp;&mdash;&nbsp;However, as categorical variables, the ACR50 and ACR70 suffer from some of the same drawbacks as the ACR20. Thus, some investigators have attempted to express changes in the ACR core set variables as a continuous measure. One such effort, the ACR-N",
"    <strong>",
"    </strong>",
"    (N for numeric), judges changes in the following three variables: swollen joint count, tender joint count, and the median of the 5 remaining core set variables, using the 0 to 100 percent improvement that is the smallest among these three measures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, the ACR-N quantifies the patient response in terms of a single number, providing a continuous variable rather than a categorical one.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361137\">",
"    <span class=\"h3\">",
"     Hybrid-ACR response",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more recent attempt to expand the ACR response criteria is the Hybrid-ACR measure. To calculate the Hybrid-ACR, first the average improvement in core set measure is determined as percent improvement (with maximizing and thus censoring worsening at 100 percent). Then, (i) the mean of the percent changes across all core set measures, and (ii) the traditional ACR response (ie, ACR20, ACR50, or ACR70 response or non-response) is determined. The Hybrid-ACR is the first of these (ie, the mean percent change across all core set variables), unless it falls within the respective range of the traditional ACR response. Under these circumstances, the response is categorized as values of 19.99, 49.99, 69.99 as long as mean core set changes lie above the traditional ACR categories that were achieved; if, however, the mean core set data lie below these traditional ACR categories, they are set to 20, 50, or 70. Thus, calculation of the Hybrid-ACR measure requires a variety of assessments to be accounted for, including the traditional ACR response evaluation. It requires additional validation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361144\">",
"    <span class=\"h2\">",
"     EULAR response criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EULAR response criteria are based upon the DAS28. These criteria categorize improvement into either good or moderate responses (",
"    <a class=\"graphic graphic_table graphicRef75446 \" href=\"UTD.htm?28/40/29325\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EULAR good response &mdash; For a good response, the decline in score must exceed 1.2 and result in the achievement of low disease activity (ie, DAS28 &lt;3.2).",
"     </li>",
"     <li>",
"      EULAR moderate response &mdash; A moderate response, on the other hand, may be achieved by a decline in the DAS28 by &gt;1.2 (without reaching low disease activity); or by a decline of 0.6 to 1.2 plus reaching at least moderate disease activity (ie, DAS28 &lt;5.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comparisons of the ACR and EULAR Response Criteria indicate that moderate EULAR responses are achieved more often than ACR20 responses in most studies. Good EULAR responses are observed more frequently than are ACR70 responses. (See",
"    <a class=\"local\" href=\"#H7361109\">",
"     'ACR response criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361165\">",
"    <span class=\"h2\">",
"     SDAI and CDAI response criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response cutoffs have been defined for the SDAI and CDAI that correspond with the traditional ACR responses; these definitions of minor, moderate, and major response have been defined as relative improvements of SDAI or CDAI of 50, 70, or 85 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7361060\">",
"     'Simplified disease activity index (SDAI)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7361067\">",
"     'Clinical disease activity index (CDAI)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361200\">",
"    <span class=\"h1\">",
"     REMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provisional definitions of remission have been developed jointly by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) for use in clinical trials and in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. These definitions will be considered provisional until the criteria have undergone validation based upon an external data set, and not only the patient data used to generate the definitions. &nbsp;",
"   </p>",
"   <p>",
"    For clinical trials, the",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    remission criteria recommend use of either of the following definitions as the primary and the other as a secondary outcome measure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SDAI &le;3.3 (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?38/51/39733?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H7361060\">",
"       'Simplified disease activity index (SDAI)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      All of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Swollen and tender joint counts (using 28 joint count) each &le;1",
"     </li>",
"     <li>",
"      Patient global assessment (on a 0 to 10 scale) &le;1",
"     </li>",
"     <li>",
"      CRP (expressed in",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      &le;1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For clinical practice, either of the clinical trial criteria, modified by exclusion of the CRP, may be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CDAI &le;2.8 (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?26/36/27205?source=see_link\">",
"       calculator 3",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H7361067\">",
"       'Clinical disease activity index (CDAI)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      All of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Swollen and tender joint counts (using 28 joint count) each &le;1",
"     </li>",
"     <li>",
"      Patient global assessment (on a 0 to 10 scale) &le;1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In concept, the state of remission constitutes a clinical condition in which no active disease is present. As noted, definitions of disease remission technically permit within their parameters some degree of active disease (",
"    <a class=\"graphic graphic_table graphicRef75446 \" href=\"UTD.htm?28/40/29325\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/11,61,63,64,81,82\">",
"     11,61,63,64,81,82",
"    </a>",
"    ]. The identification of remission is hampered practically by the presence of irreversible joint damage, which may lead to abnormalities confused with residual disease activity. In a similar manner, comorbidities such as fibromyalgia or osteoarthritis may confound the designation of remission.",
"   </p>",
"   <p>",
"    Because progressive joint destruction may occur and function may decline, albeit at comparatively slow rates, when disease activity persists even at a low level, stringent criteria are important as a means of distinguishing remission from low disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/8,11,25,83\">",
"     8,11,25,83",
"    </a>",
"    ]. In this regard, as briefly noted above, remission criteria by SDAI and CDAI, as well as Boolean-based criteria, are more stringent than DAS28 remission criteria and have been included as options in the",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    provisional definitions of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?7/33/7706/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361207\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three major points supporting the use of disease activity measures in clinical practice to try to achieve a goal of remission are the following: 1) Active RA leads to severe joint destruction, functional disability, and impaired health status; 2) Monitoring disease activity at regular, short-term intervals and appropriate modifications of DMARD therapy leads to significant functional and radiologic improvements; and, 3) Joint destruction frequently progresses even in states of low disease activity.",
"     </li>",
"     <li>",
"      Several indicators of disease activity are typically assessed in clinical trials of therapeutic agents in patients with RA. Among them, the most often measured are: swollen and tender joint counts, pain, patient and evaluator global assessments, acute phase reactants (ESR, CRP), duration of morning stiffness, fatigue, measures of function (eg, the HAQ), and of health status (eg, the Short Form 36). (See",
"      <a class=\"local\" href=\"#H7360983\">",
"       'Individual variables of disease activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various sets of individual measures have been characterized that are useful for assessing the efficacy of drug treatment of RA. These core sets include those developed by the ACR, EULAR, and",
"      <span class=\"nowrap\">",
"       WHO/ILAR.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7360990\">",
"       'Core sets of disease activity variables'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <strong>",
"       D",
"      </strong>",
"      isease",
"      <strong>",
"       A",
"      </strong>",
"      ctivity",
"      <strong>",
"       S",
"      </strong>",
"      core (DAS) and related composite indices of disease activity (eg, DAS28, SDAI, and CDAI) represent indices that provide a timely aid to clinical decision making. The SDAI and CDAI are easier to calculate than the DAS or DAS28 and define remission more stringently. (See",
"      <a class=\"local\" href=\"#H7361032\">",
"       'Composite indices for disease activity assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Responses of groups of patients to treatment in clinical trials may be based on a categorical criterion (eg, an ACR50 response, a EULAR good response, or a",
"      <span class=\"nowrap\">",
"       CDAI/SDAI",
"      </span>",
"      major response) or the mean change of a numeric index of disease activity (eg, DAS, SDAI, CDAI, ACR-N, or Hybrid ACR). DAS, SDAI, and CDAI provide measures of actual disease activity while the ACR-N and Hybrid ACR represent improvements from a series of baseline values. (See",
"      <a class=\"local\" href=\"#H7361102\">",
"       'Response criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With some preparation and minor modifications of the usual work flow in clinical settings, all of the variables comprising core data sets for RA activity assessment can be collected in a standard fashion: 1) Tender and swollen joint counts can be obtained by any health professional with appropriate training; 2) Visual analogue scales for patient and evaluator global assessments of disease activity require less than one minute to complete (",
"      <a class=\"graphic graphic_figure graphicRef50461 \" href=\"UTD.htm?29/3/29758\">",
"       figure 2",
"      </a>",
"      ); 3) Routine laboratory testing of the ESR, CRP, or both is inexpensive and widely available; 4) HAQ-DI assessments may be completed by patients in the waiting room.",
"     </li>",
"     <li>",
"      We suggest use of the CDAI to help guide treatment decisions by clinicians caring for patients with RA. The CDAI is calculated as a simple numerical sum of swollen and tender joints (using the 28 joint count), the patient global assessment and the evaluator global assessments. It can be used for clinical decision making purposes even in the absence of information about acute phase reactants. It is easy to obtain and calculate, despite the inclusion of formal joint counts.",
"      <strong>",
"      </strong>",
"      The ESR or CRP, if available, may be useful in validating the clinician's impressions based on the CDAI or other composite index of choice. (See",
"      <a class=\"local\" href=\"#H7361067\">",
"       'Clinical disease activity index (CDAI)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Provisional definitions of remission that may be used in clinical trials and clinical practice, respectively, have been developed by a joint committee of the American College of Rheumatology and the European League Against Rheumatism. (See",
"      <a class=\"local\" href=\"#H7361200\">",
"       'Remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal management of patients with RA and some degree of active disease requires serial assessments. We suggest intervals not greater than every three months, in line with the recommendations on treating RA to targeting remission or low disease activity.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/1\">",
"      Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/2\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/3\">",
"      Smolen JS, Landew&eacute; R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/4\">",
"      Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/5\">",
"      van Leeuwen MA, van der Heijde DM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994; 21:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/6\">",
"      van Leeuwen MA, van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997; 24:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/7\">",
"      Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/8\">",
"      Aletaha D, Machold KP, Nell VP, Smolen JS. The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. Rheumatology (Oxford) 2006; 45:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/9\">",
"      Drossaers-Bakker KW, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/10\">",
"      Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7:R796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/11\">",
"      Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/12\">",
"      Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/13\">",
"      Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004; 63:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/14\">",
"      Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/15\">",
"      Smolen JS, Aletaha D, Grisar JC, et al. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010; 69:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/16\">",
"      Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/17\">",
"      Devlin RD, Reddy SV, Savino R, et al. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res 1998; 13:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/18\">",
"      Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/19\">",
"      Kudo O, Sabokbar A, Pocock A, et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/20\">",
"      Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/21\">",
"      Ragab AA, Nalepka JL, Bi Y, Greenfield EM. Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol 2002; 283:C679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/22\">",
"      Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/23\">",
"      Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/24\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/25\">",
"      Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/26\">",
"      Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21:S209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/27\">",
"      Molenaar ET, Voskuyl AE, Dijkmans BA. Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission. J Rheumatol 2002; 29:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/28\">",
"      Aletaha D, Funovits J, Breedveld FC, et al. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009; 60:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/29\">",
"      Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006; 32:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/30\">",
"      Scott DL, Panayi GS, van Riel PL, et al. Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 1992; 10:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/31\">",
"      Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/32\">",
"      Boers M, Tugwell P, Felson DT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994; 41:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/33\">",
"      Tugwell P, Bombardier C. A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 1982; 9:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/34\">",
"      van der Heijde DM, van't Hof MA, van Riel PL, et al. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/35\">",
"      Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol 1993; 20:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/36\">",
"      Hart LE, Tugwell P, Buchanan WW, et al. Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol 1985; 12:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/37\">",
"      Prevoo ML, van Riel PL, van 't Hof MA, et al. Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 1993; 32:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/38\">",
"      Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/39\">",
"      Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994; 37:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/40\">",
"      Smolen JS, Breedveld FC, Eberl G, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995; 38:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/41\">",
"      Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/42\">",
"      Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/43\">",
"      Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983; 16:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/44\">",
"      Scott J, Huskisson EC. Vertical or horizontal visual analogue scales. Ann Rheum Dis 1979; 38:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/45\">",
"      Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005; 14:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/46\">",
"      Dawes PT, Fowler PD, Clarke S, et al. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 1986; 25:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/47\">",
"      Mallya RK, de Beer FC, Berry H, et al. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/48\">",
"      Plant MJ, Williams AL, O'Sullivan MM, et al. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/49\">",
"      Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol 2009; 36:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/50\">",
"      Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet 2005; 365:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/51\">",
"      van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/52\">",
"      Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/53\">",
"      Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/54\">",
"      Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum 2005; 52:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/55\">",
"      Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007; 56:3226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/56\">",
"      van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005; 64:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/57\">",
"      M&auml;kinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/58\">",
"      Balsa A, de Miguel E, Castillo C, et al. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford) 2010; 49:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/59\">",
"      Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011; 63:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/60\">",
"      Wong AL, Harker JO, Park GS, Paulus HE. Longitudinal measurement of RA disease activity in a clinical practice setting: Usefulness of the SDAI. Arthritis Rheum 2004; 50:S386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/61\">",
"      Soubrier M, Zerkak D, Gossec L, et al. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 2006; 33:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/62\">",
"      American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007; 57:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/63\">",
"      Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/64\">",
"      Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/65\">",
"      Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23:S100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/66\">",
"      Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/67\">",
"      Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/68\">",
"      Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999; 42:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/69\">",
"      Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/70\">",
"      Vita AJ, Terry RB, Hubert HB, Fries JF. Aging, health risks, and cumulative disability. N Engl J Med 1998; 338:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/71\">",
"      Stucki G, Liang MH, Stucki S, et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995; 38:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/72\">",
"      Mason JH, Anderson JJ, Meenan RF, et al. The rapid assessment of disease activity in rheumatology (radar) questionnaire. Validity and sensitivity to change of a patient self-report measure of joint count and clinical status. Arthritis Rheum 1992; 35:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/73\">",
"      Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) 2010; 62:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/74\">",
"      Pincus T, Amara I, Segurado OG, et al. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 2008; 35:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/75\">",
"      Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990; 33:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/76\">",
"      Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/77\">",
"      Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998; 41:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/78\">",
"      van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/79\">",
"      van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/80\">",
"      Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012; 71:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/81\">",
"      Prevoo ML, van Gestel AM, van T Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/82\">",
"      Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/33/7706/abstract/83\">",
"      Pincus T, Stein CM, Wolfe F. \"No evidence of disease\" in rheumatoid arthritis using methotrexate in combination with other drugs: a contemporary goal for rheumatology care? Clin Exp Rheumatol 1997; 15:591.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7494 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-ADE281C057-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7706=[""].join("\n");
var outline_f7_33_7706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7361207\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7360969\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7360976\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7360983\">",
"      INDIVIDUAL VARIABLES OF DISEASE ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7360990\">",
"      Core sets of disease activity variables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7360997\">",
"      Swollen and tender joint counts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361004\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361011\">",
"      Patient and evaluator global assessments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361018\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361025\">",
"      Other variables",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361032\">",
"      COMPOSITE INDICES FOR DISEASE ACTIVITY ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361039\">",
"      Disease activity score (DAS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7361046\">",
"      - DAS28 score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361060\">",
"      Simplified disease activity index (SDAI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361067\">",
"      Clinical disease activity index (CDAI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361074\">",
"      PHYSICAL FUNCTION ASSESSMENTS AS MEASURES OF DISEASE ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361081\">",
"      Health Assessment Questionnaire (HAQ)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361088\">",
"      The short form-36",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361095\">",
"      PATIENT-REPORTED INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32342639\">",
"      RADAI and RADAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32342654\">",
"      RAPID3 score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361102\">",
"      RESPONSE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361109\">",
"      ACR response criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7361116\">",
"      - ACR20 response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7361123\">",
"      - ACR50 and ACR70 responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7361130\">",
"      - ACR-N response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7361137\">",
"      - Hybrid-ACR response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361144\">",
"      EULAR response criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7361165\">",
"      SDAI and CDAI response criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361200\">",
"      REMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361207\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7494|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/1/36894\" title=\"figure 1\">",
"      RA disease activity cutpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/3/29758\" title=\"figure 2\">",
"      Pain and global activity scales",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/40/29325\" title=\"table 1\">",
"      RA disease activity indices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/30/26091\" title=\"table 2\">",
"      ACR RA response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?13/36/13894?source=related_link\" title=\"calculator 1\">",
"      Calculator: Rheumatoid arthritis Disease Activity Score (DAS-28)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?38/51/39733?source=related_link\" title=\"calculator 2\">",
"      Calculator: Rheumatoid arthritis Simplified Disease Activity Index (SDAI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?26/36/27205?source=related_link\" title=\"calculator 3\">",
"      Calculator: Rheumatoid arthritis Clinical Disease Activity Index (CDAI)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2234?source=related_link\">",
"      Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_33_7707="Functional capacity in RA";
var content_f7_33_7707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of functional capacity in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I: Complete",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Ability to carry on all usual duties without handicaps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class II: Adequate for normal activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Despite handicap of discomfort or limited motion at one or more joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III: Limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Only to little or none of duties of usual occupation or self-care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IV: Incapacitated, largely or wholly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Bedridden or confined to wheelchairs; little or no self care",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7707=[""].join("\n");
var outline_f7_33_7707=null;
var title_f7_33_7708="Prev midline cath infection";
var content_f7_33_7708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of infection with midline catheters",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement and relocation of catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not routinely replace midline catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of catheter-site dressing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled, or inspection of the site is necessary. Replace dressings more frequently in diaphoretic patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of administration sets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Replace administration sets, including secondary sets and add-on devices, no more frequently than at 72-hour intervals, unless clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion.",
"        <strong>",
"         No recommendation*",
"        </strong>",
"        for replacement of tubing used for intermittent infusions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Replace tubing used to administer propofol infusions every 6 or 12 hours, depending on its use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hang time for parenteral fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Complete infusion of lipids or lipid-containing parenteral nutrition fluids (eg, 3-in-1 solutions) within 24 hours of hanging the fluid. When lipid emulsions are given alone, complete the infusion within 12 hours of hanging the emulsion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Complete infusion of blood or blood products within four hours of hanging the blood.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         No recommendation*",
"        </strong>",
"        nonlipid-containing parenteral nutrition fluids.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *&nbsp;No recommendation is made when there is insufficient data in the literature.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7708=[""].join("\n");
var outline_f7_33_7708=null;
var title_f7_33_7709="Percutaneous transtracheal ventilation summary";
var content_f7_33_7709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Needle cricothyroidotomy with percutaneous transtracheal ventilation (PTV): Procedure summary and clinical tips",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Procedure summary table:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Locate the cricothyroid membrane, bound by cricoid cartilage inferiorly and thyroid cartilage superiorly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Use universal precautions and sterile technique. Cleanse the puncture site with povidone-iodine solution.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Attach a 3- to 10-mL syringe with a few mL of saline to a 13 to 18 gauge IV catheter. (AVOID needleless catheters that will not attach to a syringe.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Hold the trachea in place and provide skin tension with the thumb and middle finger of the non-dominant hand on either side of the trachea while palpating the cricothyroid membrane with the index finger.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Enter the cricothyroid membrane in its inferior-central part, directing the needle caudally (toward the feet) at an angle of 30 to 45 degrees.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. Puncture the skin and subcutaneous tissue. Advance the needle while continuously applying negative pressure on the syringe, until air bubbles are seen, confirming intratracheal placement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. Advance the catheter forward off the needle until its hub rests at the skin surface. Remove the syringe and the needle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8. Reattach the syringe to the catheter and again aspirate for air to confirm that the catheter remains in the trachea.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9. Hold the catheter firmly in place at all times or delegate an assistant to do so.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10. Connect the high pressure tubing (connected to a valve and a source of 100 percent oxygen) to the catheter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11. Give a few ventilations by delivering short bursts of gas to reconfirm placement and ensure that the equipment is functioning properly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12. Secure the transtracheal catheter with suture or a tracheostomy tie while ventilation continues.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13. Begin regular ventilation with I:E ratio 1:4 and respiratory rate 10 to 12 breaths/min in the patient without complete upper airway obstruction; adjust in patients with complete airway obstruction: I:E ratio 1:8 to 1:10 respiratory rate 5 to 6 breaths/min).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14. Monitor the patient carefully.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15. Initiate establishment of a more definitive airway (endotracheal tube or tracheostomy) which may require consultation with anesthesiology and/or otolaryngology.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Procedure tips table:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. In older children, feel the laryngeal cartilage and then go caudad to identify cricothyroid membrane.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. In infants and younger children, follow the tracheal rings superiorly to locate the prominence of the cricoid cartilage. The cricothyroid membrane, even if not felt clearly, is just superior to the cricoid cartilage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. If the cricothyroid membrane cannot be located with certainty in an infant or a young child, the catheter can be introduced between tracheal cartilages.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. The cricothyroid membrane should be punctured below its central part to avoid blood vessels.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. One person should be assigned to hold the hub of the IV catheter in place over the neck at all times.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. A pre-assembled system including all the necessary components for needle cricothyrotomy and PTV should be readily available in all resuscitation areas.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. The system should be used in regular mock codes to improve familiarity of the medical, nursing, and respiratory therapy staff.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7709=[""].join("\n");
var outline_f7_33_7709=null;
var title_f7_33_7710="Accuracy of US diverticulitis";
var content_f7_33_7710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of ultrasonography in the detection of diverticulitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity",
"       </td>",
"       <td class=\"subtitle1\">",
"        PPV",
"       </td>",
"       <td class=\"subtitle1\">",
"        NPV",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        130",
"       </td>",
"       <td class=\"centered\">",
"        98",
"       </td>",
"       <td class=\"centered\">",
"        98",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        [1]",
"       </td>",
"       <td class=\"centered\">",
"        Schwerk WB, et al",
"       </td>",
"       <td class=\"centered\">",
"        1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        161",
"       </td>",
"       <td class=\"centered\">",
"        98",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        [2]",
"       </td>",
"       <td class=\"centered\">",
"        Schwerk WB, et al",
"       </td>",
"       <td class=\"centered\">",
"        1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        143",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        [3]",
"       </td>",
"       <td class=\"centered\">",
"        Zielke A, et al",
"       </td>",
"       <td class=\"centered\">",
"        1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        64",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        [4]",
"       </td>",
"       <td class=\"centered\">",
"        Pradel JA, et al",
"       </td>",
"       <td class=\"centered\">",
"        1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        934",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        [5]",
"       </td>",
"       <td class=\"centered\">",
"        Chou YH, et al",
"       </td>",
"       <td class=\"centered\">",
"        2001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [6]",
"       </td>",
"       <td class=\"centered\">",
"        Hollerweger A, et al",
"       </td>",
"       <td class=\"centered\">",
"        2001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        247",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        76",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [7]",
"       </td>",
"       <td class=\"centered\">",
"        Moll R, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        203",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [8]",
"       </td>",
"       <td class=\"centered\">",
"        Ripolles T, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        63",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [9]",
"       </td>",
"       <td class=\"centered\">",
"        Farag SM, et al",
"       </td>",
"       <td class=\"centered\">",
"        2004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        328 (18)",
"       </td>",
"       <td class=\"centered\">",
"        89",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        [10]",
"       </td>",
"       <td class=\"centered\">",
"        Lee MW, et al",
"       </td>",
"       <td class=\"centered\">",
"        2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1021 (118)",
"       </td>",
"       <td class=\"centered\">",
"        61",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        [11]",
"       </td>",
"       <td class=\"centered\">",
"        Van Randen A, et al",
"       </td>",
"       <td class=\"centered\">",
"        2011",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Parentheses indicate the number of patients with proven diverticulitis, if noted.",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; NPV: negative predictive value; NE: not evaluable.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Schwerk WB, Schwarz S, Rothmund M. Sonography in acute colonic diverticulitis. A prospective study. Dis Colon Rectum 1992; 35:1077.",
"       </li>",
"       <li>",
"        Schwerk WB, Schwarz S, Rothmund M, Arnold R. Colon diverticulitis: imaging diagnosis with ultrasound--a prospective study. Z Gastroenterol 1993; 31:294.",
"       </li>",
"       <li>",
"        Zielke A, Hasse C, Nies C, Kisker O, Voss M, Sitter H et al. Prospective evaluation of ultrasonography in acute colonic diverticulitis. Br J Surg 1997; 84:385.",
"       </li>",
"       <li>",
"        Pradel JA, Adell JF, Taourel P, Djafari M, Monnin-Delhom E, Bruel JM. Acute colonic diverticulitis: prospective comparative evaluation with US and CT. Radiology 1997; 205:503.",
"       </li>",
"       <li>",
"        Chou YH, Chiou HJ, Tiu CM, Chen JD, Hsu CC, Lee CH et al. Sonography of acute right side colonic diverticulitis. Am J Surg 2001; 181:122.",
"       </li>",
"       <li>",
"        Hollerweger A, Macheiner P, Rettenbacher T, Brunner W, Gritzmann N. Colonic diverticulitis: diagnostic value and appearance of inflamed diverticula-sonographic evaluation. Eur Radiol 2001; 11:1956.",
"       </li>",
"       <li>",
"        Moll R, Mittelkotter U, Reith HB, Schindler G, Thiede A. Which imaging in case of sigmoid diverticulitis? The value of ultrasound (Conventional B-mode in combination with hydrocolonsonography and colour flow Doppler) in comparison to the well-established modalities like contrast enema and helical computertomography. Zentralbl Chir 2002; 127:297.",
"       </li>",
"       <li>",
"        Ripolles T, Agramunt M, Martinez MJ, Costa S, Gomez-Abril SA, Richart J. The role of ultrasound in the diagnosis, management and evolutive prognosis of acute left-sided colonic diverticulitis: a review of 208 patients. Eur Radiol 2003; 13:2587.",
"       </li>",
"       <li>",
"        Farag SM, Wustner M, Sturm J, Werner A, Diehl SJ, Duber C et al. Primary diagnostics of acute diverticulitis of the sigmoid. Ultraschall Med 2004; 25:342.",
"       </li>",
"       <li>",
"        Lee MW, Kim YJ, Jeon HJ, Park SW, Jung SI, Yi JG. Sonography of acute right lower quadrant pain: importance of increased intraabdominal fat echo. AJR Am J Roentgenol. 2009; 192:174.",
"       </li>",
"       <li>",
"        Van Randen A, Lam&eacute;ris W, van Es HW, van Heesewijk HP, van Ramshorst B, Ten Hove W, Bouma WH, van Leeuwen MS, van Keulen EM, Bossuyt PM, Stoker J, Boermeester MA; OPTIMA Study Group. A comparison of the accuracy of ultrasound and computed tomography in common diagnoses causing acute abdominal pain. Eur Radiol. 2011; 21: 1535.",
"       </li>",
"       <ol>",
"       </ol>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7710=[""].join("\n");
var outline_f7_33_7710=null;
var title_f7_33_7711="Electrophoresis hgb H";
var content_f7_33_7711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrophoresis for hemoglobin H: Alkaline cellulose acetate gel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a hemoglobin electrophoresis run at alkaline pH on cellulose acetate gel. Lane 2 is a commercial standard containing approximately equal amounts of hemoglobins A, F, S, and C. Lane 1 is a hemoglobin sample from a patient with myelodysplastic syndrome/acute myeloid leukemia, a population of hypochromic-microcytic red cells, and acquired hemoglobin H disease. A minor fast-migrating band, hemoglobin H, is seen along with hemoglobin A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly supplied by Dr. German Pihan, Department of Pathology, Beth Israel Deaconess Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_33_7711=[""].join("\n");
var outline_f7_33_7711=null;
